TechBio News: Automated Image Diagnosis Europe (part III)
MetaphysicalCells: A newsletter about Science, Technology and AI Drug Discovery
Hi everyone 👋 and welcome back to another edition of MetaphysicalCells 🛸 only for paid subscribers, this time is all about Medical Imaging Data and Automated Image Diagnosis in Europe (part III) (🔐).
For the first and second part:
TechBio News: Automated Image Diagnosis Europe (part I) (🔐) and
TechBio News: Automated Image Diagnosis Europe (part II) (🔐).
Automated Image Diagnosis Europe (part III)
▶️ Avicenna.ai
Avicenna.AI in France (Empowering Radiology With AI-based Tools) offers AI solutions tailored for emergency radiology and incidental findings. Through collaboration with experts and software engineers, they enhance radiologists' efficiency by streamlining their manual tasks with cutting-edge tools for 🔹head, 🔹chest and 🔹spine. More specifically, Avicenna.AI provides efficient solutions not only for the detection of traumatic brain injury (TBI) and hemorrhagic stroke, but also for the identification and quantification of acute ischemic stroke. Their tools excel in overcoming the challenges associated with the diversity of chest conditions, non-specific indicators, and the potential overlap of symptoms with other diseases.
On September 19, 2024, Avicenna.AI received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its 🔹CINA-CSpine tool, designed to support the detection and triage of cervical spine fractures from CT images (Avicenna.AI gets FDA nod for CINA-CSpine). CINA-CSpine was validated on more than 300 noncontrast CT scans provided by multiple sources in the U.S. and Europe and acquired from 36 different scanner models across five vendors, according to the firm. On December 16, 2024, Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, and Avicenna.AI announced the integration of Avicenna.AI's 🔹CINA-iPE (detects incidental pulmonary embolism, PE) and 🔹CINA-ASPECTS (assesses the ASPECTS, Alberta Stroke Program Early CT Score, from CT brain images) tools into the Viz.ai OneTM platform, a combination that provides radiologists and specialists with additional insights from computed tomography (CT) scans, to advance fast and accurate decision-making, driving better patient care (Viz.ai Integrates Avicenna.AI's Tools for ASPECTS Stroke Severity Assessment and Incidental Pulmonary Embolism into Viz.ai One Platform).
As of March 2025, RMS Medical Devices, a leader in innovative medical technologies, has strategic commercial partnership with Avicenna.AI, that brings cutting-edge AI-powered diagnostic tools to healthcare providers in Belgium, the Netherlands, and Luxembourg (Benelux), enhancing patient care and operational efficiency across the region (RMS Medical Devices Announces Strategic Commercial Partnership With Avicenna.AI In The Benelux Region).
Apart from RMS Medical Devices, Avicenna.AI also has a strategic partnership with TIM, a major player in teleradiology in mainland France and the French overseas territories (TIM & AVICENNA.AI Announce Strategic Partnership To Strengthen Medical Imaging In France).